Last reviewed · How we verify

NCT06734728

Post-marketing Study for the Evaluation of Profilm Cold Sores

Completed NA Last updated 1 April 2025
What this trial tests

NA trial testing Profilm Cold Sores in Cold Sores in 35 participants. Completed in 29 March 2023.

Timeline
13 December 2022
Primary endpoint
15 December 2022
29 March 2023

Quick facts

Lead sponsori+Med S.Coop.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment35
Start date13 December 2022
Primary completion15 December 2022
Estimated completion29 March 2023
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

i+Med S.Coop. — full company profile →

Who can join

18 and older, any sex, with Cold Sores. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Experimental clinical study with a post-marketing, prospective, intra-subject controlled design to evaluate the efficacy and safety of the use of a medical device for the treatment of cold sores, over a maximum period of two weeks (or until the outbreak has resolved).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other i+Med S.Coop. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06734728.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing